Rallybio (NASDAQ:RLYB) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Rallybio (NASDAQ:RLYB) to a hold rating in a research report report published on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Rallybio in a report on Monday, December 29th. Four analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Reduce”.

Rallybio Price Performance

Shares of Rallybio stock opened at $8.22 on Friday. The business’s 50 day simple moving average is $6.97 and its two-hundred day simple moving average is $5.77. The stock has a market capitalization of $43.48 million, a P/E ratio of -3.21 and a beta of -1.13. Rallybio has a one year low of $1.76 and a one year high of $11.49.

Rallybio (NASDAQ:RLYB) last released its quarterly earnings data on Thursday, March 12th. The company reported ($1.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.01. Rallybio had a negative return on equity of 56.93% and a negative net margin of 1,046.39%.The firm had revenue of $0.22 million during the quarter, compared to analyst estimates of $0.10 million. Sell-side analysts expect that Rallybio will post -1.34 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Rallybio

Several institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC increased its stake in shares of Rallybio by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock valued at $170,000 after buying an additional 2,996 shares during the period. XTX Topco Ltd lifted its stake in Rallybio by 64.6% in the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock worth $67,000 after acquiring an additional 38,205 shares during the period. Susquehanna International Group LLP lifted its stake in Rallybio by 485.9% in the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after acquiring an additional 113,031 shares during the period. Renaissance Technologies LLC boosted its holdings in Rallybio by 16.9% in the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after acquiring an additional 120,892 shares in the last quarter. Finally, Citadel Advisors LLC boosted its holdings in Rallybio by 576.1% in the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after acquiring an additional 373,821 shares in the last quarter. Hedge funds and other institutional investors own 90.34% of the company’s stock.

Rallybio Company Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.